Atovaquone-HSA Nano-Drugs Enhance the Efficacy of PD-1 Blockade Immunotherapy by Alleviating Hypoxic Tumor Microenvironment

The authors exploited atovaquone/albumin nanoparticles to improve bioavailability and tumor targeting of atovaquone, enhancing the efficacy of anti-PD-1 therapy by normalizing tumor hypoxia.